NJ FamilyCare does not cover Wegovy or Zepbound for weight loss

NJ FamilyCare does not cover drugs for weight loss alone. The Department of Human Services told the Legislature that it covers them only in limited cases: Wegovy for cardiovascular disease, Zepbound for sleep apnea, and some children under the federal EPSDT benefit. A 2026 bill to require coverage of anti-obesity medications in NJ FamilyCare and the state employee plans was pre-filed but is not law.1216

The Drug Utilization Review Board recommends statewide protocols for the GLP-1s covered for uses other than weight loss; the managed care plans apply them. The criteria below are from the protocols as Aetna Better Health of New Jersey posts them.67345

• Wegovy, cardiovascular path: established cardiovascular disease (such as a prior heart attack, stroke or TIA, symptomatic peripheral arterial disease or past revascularization), a BMI of 27 or more, prescribed by or with a cardiologist, vascular specialist or endocrinologist, with documented lifestyle counseling and use with a reduced-calorie diet and more physical activity.
• Wegovy, MASH path: noncirrhotic MASH with documented liver fibrosis stage F2 or F3, prescribed by or with a hepatologist, gastroenterologist or endocrinologist.
• Wegovy: no other GLP-1 at the same time; initial approval 7 months, renewal 12 months.
• Zepbound: moderate to severe obstructive sleep apnea with an apnea-hypopnea index of at least 15 events per hour on a study in the past 12 months, a BMI of 30 or more, used with a reduced-calorie diet and more physical activity, no other GLP-1 at the same time; initial approval 6 months, renewal 12 months.

Coverage for other uses the FDA has approved:

• Wegovy (injection), cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight: Covered with prior authorization136
• Wegovy (injection), noncirrhotic MASH with moderate to advanced liver fibrosis: Covered with prior authorization56
• Zepbound, moderate to severe obstructive sleep apnea with obesity: Covered with prior authorization147

What changed, and when:

CMS BALANCE model: CMS says state Medicaid agencies can join BALANCE from May 2026 through January 1, 2027, but its model page names no participating states, and we found no New Jersey announcement that NJ FamilyCare has joined.9

The SHBP and SEHBP prescription plans cover GLP-1s for weight loss. Since Nov. 1, 2025, members pay a $45 copay per 30-day supply for non-diabetic GLP-1s such as Wegovy, Zepbound and Saxenda ($135 for 90 days by mail), except in the high-deductible plans, and the plan-year 2027 copay sheets keep that copay. The January 2026 SHBP formulary lists Wegovy, Saxenda and the Zepbound pens with prior authorization and quantity limits, and excludes the Zepbound vials. A 2025 plan design resolution says that once a lifestyle management program starts, members who do not take part will pay $125 per 30-day supply.1011121314

Pharmacy benefit: Optum Rx (prescription drug plans); Horizon and Aetna (medical plans).

Marketplace (ACA) plans: New Jersey's essential health benefits benchmark plan for 2025 to 2027, a Horizon small-group EPO, excludes drugs used solely for weight loss.17

NJ FamilyCare has no single statewide preferred drug list for the diabetes GLP-1s: each managed care plan keeps its own formulary. On Aetna Better Health of New Jersey's type 2 diabetes protocol, Ozempic is on the formulary with step therapy, while Mounjaro, Rybelsus and Trulicity are non-formulary and need prior authorization.82

In 2025, NJ FamilyCare paid for 128,292 GLP-1 prescriptions, $132.7 million before rebates: 13 per 1,000 residents, against 32 across the states and DC, 41st of 51.67 It reimbursed 6 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 65 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4243333429372232

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2930312237383940413635
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.242622

In 2024, Medicare Part D drug plans paid for 503,609 GLP-1 claims from prescribers in New Jersey, $679.2 million in total drug cost.68

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.72 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check New Jersey on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7374 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

We found no action on compounded GLP-1s by New Jersey’s board of pharmacy or attorney general on their own sites.

The FDA’s register lists 8 outsourcing facilities (503B) in New Jersey, as of November 6, 2026; 4 show no inspection date and 4 were issued a Form 483.69

FDA warning letters naming a GLP-1, sent to a company in New Jersey:70